EUVIMEDEUVIMED entdecken
Crossref

Synthesis of Two Versions of Carbon‐14‐Labeled ARV‐110: An Androgen Receptor PROTAC Degrader for Prostate Cancer

Xiang-Sheng Dai, Bin Dong, Lei Xu iD, Zheng-Min Yang

Journal of Labelled Compounds and Radiopharmaceuticals · 2025

DOI: 10.1002/jlcr.4154 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Labelled Compounds and Radiopharmaceuticals, 2025. Verfasst von Xiang-Sheng Dai und 3 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Nuclear-Agricultural Science, Key Laboratory of Nuclear Agricultural Sciences of Ministry of Agriculture, Zhejiang University, Hangzhou,…. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Carbon Radioisotopes, Receptors, Androgen, Piperazines. Die Arbeit nennt 16 Literaturangaben. Gefördert von: Key Project of Special Development Foundation of Shanghai Zhangjiang National Innovation Demonstration Zone.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

N ‐((1 R ,4 R )‐4‐(3‐Chloro‐4‐cyanophenoxy)cyclohexyl)‐6‐(4‐((4‐(2‐(2,6‐dioxopiperidin‐3‐yl)‐6‐fluoro‐1,3‐dioxoisoindolin‐5‐yl)piperazin‐1‐yl)methyl)piperidin‐1‐yl)pyridazine‐3‐carboxamide (ARV‐110) is a proteolysis‐targeting chimera (PROTAC) designed against the androgen receptor (AR), which shows great potential for treating AR‐dependent diseases, such as prostate cancer. To support preclinical safety evaluations as well as studies of drug metabolism and pharmacokinetics, two versions of carbon‐14‐labeled ARV‐110 were synthesized: N ‐((1 R ,4 R )‐4‐(3‐chloro‐4‐cyanophenoxy)cyclohexyl)‐6‐(4‐((4‐(2‐(2,6‐dioxopiperidin‐3‐yl)‐6‐fluoro‐1,3‐[1,3‐ 14 C2]dioxoisoindolin‐5‐yl)piperazin‐1‐yl)methyl)piperidin‐1‐yl)pyridazine‐3‐carboxamide ( 14 C‐ARV‐110‐ a ) and N ‐((1 R ,4 R )‐4‐(3‐chloro‐4‐[ cyano ‐ 14 C]cyanophenoxy)cyclohexyl)‐6‐(4‐((4‐(2‐(2,6‐dioxopiperidin‐3‐yl)‐6‐fluoro‐1,3‐dioxoisoindolin‐5‐yl)piperazin‐1‐yl)methyl)piperidin‐1‐yl)pyridazine‐3‐carboxamide ( 14 C‐ARV‐110‐ b ). The synthesis of 14 C‐ARV‐110‐ a was initiated from 1,2‐dibromo‐4,5‐difluorobenzene and zinc cyanide‐ 14 C (Zn( 14 CN)₂), while 14 C‐ARV‐110‐ b was prepared from 2‐chloro‐4‐fluoro[ cyano ‐ 14 C]benzonitrile.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsCarbon RadioisotopesReceptors, AndrogenPiperazinesPyridazinesMaleHumansChemistry Techniques, SyntheticRadiochemistryIsotope Labeling

Stichwörter der Autor:innen

ARV‐110PROTACcarbon‐14isotopically labeled synthesistargeted protein degrader

Substanzen

Carbon RadioisotopesReceptors, AndrogenCarbon-14PiperazinesPyridazines

Autor:innen und Institutionen

  • Institute of Nuclear-Agricultural Science, Key Laboratory of Nuclear Agricultural Sciences of Ministry of Agriculture, Zhejiang University, Hangzhou, China.
  • Science & Technology Innovation Center, Zhejiang Isotope Technologies Co., Ltd, Hangzhou, Zhejiang Province, China.
  • Zhejiang Isotope Labeled Compounds Co., Ltd, Jiaxing, Zhejiang Province, China.

ORCID-Profile: Lei Xu

Förderung

  • Key Project of Special Development Foundation of Shanghai Zhangjiang National Innovation Demonstration Zone

Zitieren

APA

Dai, X. S., Dong, B., Xu, L., & Yang, Z. M. (2025). Synthesis of Two Versions of Carbon‐14‐Labeled ARV‐110: An Androgen Receptor PROTAC Degrader for Prostate Cancer. Journal of Labelled Compounds and Radiopharmaceuticals. https://doi.org/10.1002/jlcr.4154

Vancouver

Dai XS, Dong B, Xu L, Yang ZM. Synthesis of Two Versions of Carbon‐14‐Labeled ARV‐110: An Androgen Receptor PROTAC Degrader for Prostate Cancer. Journal of Labelled Compounds and Radiopharmaceuticals. 2025. doi:10.1002/jlcr.4154

BibTeX
@article{Dai2025,
  author = {Dai, Xiang-Sheng and Dong, Bin and Xu, Lei and Yang, Zheng-Min},
  title = {Synthesis of Two Versions of Carbon‐14‐Labeled ARV‐110: An Androgen Receptor PROTAC Degrader for Prostate Cancer},
  journal = {Journal of Labelled Compounds and Radiopharmaceuticals},
  year = {2025},
  doi = {10.1002/jlcr.4154}
}
Kostenlos starten →